A phase 2, multicenter, single-arm of Zanubrutinib

 PDF   1   06/2020

Trial in progress: A phase 2, multicenter, single-arm of Zanubrutinib (BGB-3111) in patients with previously treated B-Cell Malignancies intolerant of prior treatment of Ibrutinib or Acalabrutinib

Nice to see you!

For newest details on our ESMO materials in a personal video meeting, please click here!
Service